• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
IMCS

IMCS

A leader in recombinant enzymes and automated micro-chromatography technologies

  • ABOUT
    • ABOUT IMCS
    • QUALITY POLICY
    • RESEARCH AT IMCS
    • CAREERS
  • PRODUCTS
    • IMCSzyme®
      • IMCSzyme E1F
      • IMCSzyme RT
      • IMCSzyme® CATALOG
    • IMCStips®
      • APPLICATIONS
        • AFFINITY
        • SIZE EXCLUSION
        • NUCLEIC ACIDS
        • ION EXCHANGE
        • REVERSE PHASE
        • PHOSPHOPEPTIDE
      • IMCStips® CATALOG
      • AUTOMATION PLATFORMS
        • DYNAMIC DEVICES
        • HAMILTON
        • INTEGRA
        • TECAN
        • OPENTRONS
        • ANALYTIK JENA
    • SULFATASES
      • Sulfazyme
      • Sulfazyme™ DS
      • Sulfazyme™ β-AS
    • GLYCO REAGENTS
      • GLYCOLIPIDS
      • ACTIVATED SUGARS
      • BIOSYNTHETIC ENZYMES
      • SMALL MOLECULES
    • SPHINGOSINES
    • OTHER PROTEINS
      • PURIFIED STREPTAVIDIN
      • B. pi. β-glucuronidase variant
  • SERVICES
    • BETA-GLUCURONIDASES & SULFATASES
      • β-GLUCURONIDASE VALIDATION SERVICES
      • HIGH-THROUGHPUT TOXICOLOGY WORKFLOWS
    • IMCStips®
      • SAMPLE PREPARATION AUTOMATION
      • HIGH-THROUGHPUT METHOD DEVELOPMENT
      • AUTOMATION PLATFORMS
        • DYNAMIC DEVICES
        • HAMILTON
        • INTEGRA
        • TECAN
        • OPENTRONS
        • ANALYTIK JENA
    • OTHER SERVICES
      • GLYCAN PRODUCTION (Coming Soon)
      • R&D COLLABORATIONS
      • EXTRACELLULAR VESICLES
  • RESOURCES
    • FAQ
    • IMCSZYME RESOURCES
    • IMCSTIPS RESOURCES
    • SAFETY DATA SHEETS
    • CERTIFICATE OF ANALYSIS
  • LATEST NEWS
    • LATEST NEWS
    • PODCAST
    • BLOG
    • EVENTS
    • WEBINARS
  • SHOP
  • CONTACT
  • en
    • en
    • es
    • fr
    • de
    • zh-CN

THE HIDDEN COSTS OF LENGTHY DRUG INCUBATION TIMES

February 11, 2019

Drugs of abuse testing is, in some ways, an imperfect science. With new innovations developing within the industry almost annually, best-practices for drug testing have become muddled, varying sharply from lab to lab.

One of the most common effects of an inefficient drug testing process, lengthy incubation times can have a significant negative impact on results, reliability, and ROI.

Image of empty drug testing sample containers with green lids.

Lengthy Incubations Can Put Results into Question

If the primary goal of drug testing is to report verifiable use of drugs of abuse, long incubation periods are working against that goal. Incubation time impacts all samples differently through factors like the makeup of urine, pH levels, and even temperature of the sample. The longer a sample incubates, the more its volume of testable enzymesdecreases. The key to laboratories having the ability to provide accurate results every time lies in streamlining the incubation period.

Efficiency Increases Laboratory Throughput

Longer-than-necessary incubation periods for drug test samples don’t just hamper the testing process itself, they hamstring the testing facility. Commercial laboratories, healthcare facilities, and research organizations all operate with a finite number of resources, most importantly: time. In the laboratory environment, lost time equates to higher labor costs, lower throughput, and in the end, a drain on the bottom line of high-throughput screening operations everywhere.

Long Incubations Are No Longer Necessary for Drug Testing

Labs around the world, pushed to the edge in terms of resources and ability, have finally begun to demand better drug testing solutions. Enter: IMCSzyme. Developed by the team at Integrated Micro-Chromatography Systems, LLC, IMCSzyme was designed to optimize the process of drug testing. A pure beta-Glucuronidase enzyme, IMCSzyme hydrolyzes multiple drug classes quickly and efficiently with virtually no incubation period.

In fewer than fifteen minutes, IMCS can achieve over 90% recovery hydrolysis for a variety of difficult-to-detect drugs including several commonly abused opiates. With no incubation at all, IMCSzyme achieves nearly 100% hydrolysis for drugs like amitriptyline and oxazepam; in less then 30 minutes, over 85% hydrolysis can be achieved for opiates like Morphine-3, Codeine, and Dihydrocodeine, marking a significant improvement over results garnered by other traditional beta-Glucuronidases.

Long incubation periods are not a necessary evil of drug testing. Shorter incubations produce better results, more repeatable outcomes, and reduce inefficiencies on the backend. The faster a sample can be tested and reported, the sooner drugs of abuse sufferers can begin to get help.

Would you like more information on the groundbreaking technical specifications of IMCSzyme? Reach out to the dedicated team at IMCS today to learn more about how IMCSzyme can improve your process right away.

Category: BLOG, LATEST NEWS
Previous Post:3 CHANGES ON THE HORIZON FOR PRECISION MEDICINE
Next Post:3 RECENT ADVANCEMENTS IN ANTI-DOPING TESTING FOR ATHLETES

Customize Your Workflow

IMCS recognizes our customers’ needs vary, which is why we provide tailored tools and services to help you reach your laboratory’s goals.

VIEW OUR CUSTOM SOLUTIONS

ABOUT IMCS

INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. (IMCS) IS A BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING TOOLS AND SERVICES THAT HELP PAVE THE WAY FOR THE FUTURE OF PRECISION MEDICINE. WE STRIVE TO ADDRESS THE GROWING NEEDS OF CLINICAL AND RESEARCH LABORATORIES THROUGH ADVANCED TECHNOLOGIES THAT INCREASE TESTING EFFICIENCY AND ACCURACY.

STAY UP TO DATE

WANT REGULAR UPDATES ON OUR INNOVATIVE PRODUCTS?
Sign up to receive exclusive emails and offers from IMCS.
!
!
!
Subscribe
Something went wrong. Please check your entries and try again.

ABOUT

ABOUT IMCS

CAREERS

QUALITY POLICY

RESEARCH AT IMCS

PRODUCTS

IMCSZYME

IMCSZYME RT

IMCSTIPS

PROTEINS, ENZYMES, RESINS

GLYCO REAGENTS

TERMS

TERMS OF USE

PRIVACY POLICY

STANDARD TERMS AND CONDITIONS

FCOI POLICY

CONNECT WITH US

IMCS, Inc. Headquarters
110 Centrum Drive
Irmo, SC 29063

  • IMCS LinkedIn Page
  • IMCS Facebook Page
  • IMCS Twitter Page

COPYRIGHT © 2026 · IMCS · ALL RIGHTS RESERVED ·

Return to top

Caleb-Schlachter-for-web

Caleb R. Schlachter, Ph.D.

Principal Scientist
Caleb R. Schlachter, Ph.D., as the Principal Scientist at IMCS, leads and provides guidance for several research and development projects that involve proteins, including enzymes for glycan hydrolysis and glycan synthesis. He has co-authored multiple patents, posters, and peer-reviewed articles on β-glucuronidases and sulfatases.
Gray Amick for web

Gray D. Amick, Ph.D.

Director of Operations
Gray D. Amick, Ph.D., is the Director of Operations at IMCS with over 26 years of experience in forensic DNA analysis and toxicology. Prior to joining IMCS, he led forensic DNA testing for the Richland County Sheriff’s Department as technical leader and lab director. He has been court-qualified as an expert over 100 times and has authored and co-authored multiple posters and peer-reviewed articles.
Amanda M Headshot

Amanda C. McGee

Research Scientist
Amanda C. McGee is a Research Scientist at IMCS involved with enzyme characterizations, new analytical method developments, and advanced technical support. She joined IMCS with several years of experience in analytical testing for active pharmaceutical ingredients as per cGMP, USP and ICH guidelines. She has co-authored peer reviewed articles in the Journal of Analytical Toxicology and presented research at national and international conferences.
Andrew_Headshot

L. Andrew Lee, Ph.D.

Co-Founder and Chief Scientific Officer
L. Andrew Lee, Ph.D. co-founded IMCS and leads research and development efforts in enzyme engineering and automated micro-chromatography workflows. He directs new market efforts in glycan synthesis, supported by three NIH Fast-Track awards.

Get started with 2N1 below

"*" indicates required fields

Name*
Would you be interested in joining the 2N1 beta program?*
Which product are you interested in? (select all that apply)*
What are your current purification workflows? (select all that apply)*
Please select your automation platform(s) (select all that apply)*
How soon are you planning on evaluating 2N1?*
Consent*

DOWNLOAD OUR POSTERS

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Please select the posters you would like to download*
Name*
Please provide a valid email so we can send you the download link.
Location*
Automated Liquid Handling System
Contact preferences*
Consent*

Podcast Form

"*" indicates required fields

Name*
How would you like to connect?*
Please let us know what's on your mind. Have a question for us? Ask away.

Ready for a change? Get your FREE sample of IMCSzyme® RT today.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
Consent*